JP2024508498A - 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ - Google Patents

睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ Download PDF

Info

Publication number
JP2024508498A
JP2024508498A JP2023552525A JP2023552525A JP2024508498A JP 2024508498 A JP2024508498 A JP 2024508498A JP 2023552525 A JP2023552525 A JP 2023552525A JP 2023552525 A JP2023552525 A JP 2023552525A JP 2024508498 A JP2024508498 A JP 2024508498A
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmacologically acceptable
reboxetine
oxybutynin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508498A5 (https=
Inventor
ミラー，ローレンス，ジー．
ファーカス，ロナルド
タラント－モンテムッロ，ルイージ
Original Assignee
アプニメッド，インコーポレイテッド（デラウェア）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプニメッド，インコーポレイテッド（デラウェア） filed Critical アプニメッド，インコーポレイテッド（デラウェア）
Publication of JP2024508498A publication Critical patent/JP2024508498A/ja
Publication of JP2024508498A5 publication Critical patent/JP2024508498A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023552525A 2021-03-04 2022-03-03 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ Pending JP2024508498A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156463P 2021-03-04 2021-03-04
US63/156,463 2021-03-04
PCT/US2022/018604 WO2022187420A1 (en) 2021-03-04 2022-03-03 Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea

Publications (2)

Publication Number Publication Date
JP2024508498A true JP2024508498A (ja) 2024-02-27
JP2024508498A5 JP2024508498A5 (https=) 2025-03-10

Family

ID=80999274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552525A Pending JP2024508498A (ja) 2021-03-04 2022-03-03 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ

Country Status (8)

Country Link
US (1) US20240139200A1 (https=)
EP (1) EP4301353A1 (https=)
JP (1) JP2024508498A (https=)
KR (1) KR20230154186A (https=)
CN (1) CN116916909A (https=)
AU (1) AU2022231133A1 (https=)
CA (1) CA3210092A1 (https=)
WO (1) WO2022187420A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
JP2005535681A (ja) * 2002-07-25 2005-11-24 ファルマシア コーポレイション レボキセチン含有徐放錠
WO2019152475A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
JP2020517719A (ja) * 2017-04-28 2020-06-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 睡眠時無呼吸を治療する方法及び組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
JP2005535681A (ja) * 2002-07-25 2005-11-24 ファルマシア コーポレイション レボキセチン含有徐放錠
JP2020517719A (ja) * 2017-04-28 2020-06-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 睡眠時無呼吸を治療する方法及び組成物
WO2019152475A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELISA PERGER ET AL.: " Reboxetine Plus Oxybutynin for Obstructed Sleep Apnea Treatment A 1-Week Randomized, Placebo-Contro", SSRN, JPN7025005674, 24 December 2025 (2025-12-24), pages 1 - 27, ISSN: 0005763350 *
INSTITUTO AUXOLOGICO ITALIANO: "Study of AD128 Versus Plasebo in Obstructive Sleep Apenea", CLINICALTRIALS.GOV, JPN7025005673, 29 December 2020 (2020-12-29), ISSN: 0005763351 *
RAPHAEL HEINZER: "Effect of AD128 to Treat Obstructive Sleep Apenea", CLINICALTRIALS.GOV, JPN7025005672, 23 October 2020 (2020-10-23), ISSN: 0005763352 *

Also Published As

Publication number Publication date
CN116916909A (zh) 2023-10-20
CA3210092A1 (en) 2022-09-09
EP4301353A1 (en) 2024-01-10
AU2022231133A1 (en) 2023-09-21
US20240139200A1 (en) 2024-05-02
KR20230154186A (ko) 2023-11-07
WO2022187420A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US20260007618A1 (en) Methods and compositions for treating sleep apnea
JP7705348B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
US20240075035A1 (en) Methods and compositions for treating sleep apnea
US20240277719A1 (en) Norepinephrine reuptake inhibitors for treating sleep apnea
US20230135373A1 (en) Methods and compositions for treating sleep apnea
JP2024508498A (ja) 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ
US20240173337A1 (en) Methods and compositions for treating sleep apnea
KR20240053061A (ko) 수면 무호흡증을 치료하기 위한 방법 및 조성물
US20250302814A1 (en) Methods and compositions for treating sleep apnea
JP2025527796A (ja) 睡眠時無呼吸を治療するための方法及び組成物
US20250009720A1 (en) Methods and compositions for treating sleep apnea
CN117615764A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260105